A mouse mutant p53 product recognized by CD4+ and CD8+ T cells.
about
Human tumor antigens recognized by T lymphocytesImmunologic aspect of ovarian cancer and p53 as tumor antigen.Genetic basis for clinical response to CTLA-4 blockade in melanomaIdentification of a 17beta-hydroxysteroid dehydrogenase type 12 pseudogene as the source of a highly restricted BALB/c Meth A tumor rejection peptide.The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice.Serologic responses in patients with malignant mesothelioma: evidence for both public and private specificities.A novel receptor on allograft (H-2d)-induced macrophage (H-2b) toward an allogeneic major histocompatibility complex class I molecule, H-2Dd, in mice.Endogenous c-src as a determinant of the tumorigenicity of src oncogenes.Targeting p53 as a general tumor antigen.Apoptosis in human autoimmune diseases.Enhancement of anti-tumor immunity by tumor cells transfected with the secondary lymphoid tissue chemokine EBI-1-ligand chemokine and stromal cell-derived factor-1alpha chemokine genes.Split T cell tolerance against a self/tumor antigen: spontaneous CD4+ but not CD8+ T cell responses against p53 in cancer patients and healthy donors.Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma.Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?The immunoprotective MHC II epitope of a chemically induced tumor harbors a unique mutation in a ribosomal protein.Therapeutic vaccination with tumor cells that engage CD137.Follicle-stimulating hormone receptor is expressed in human ovarian surface epithelium and fallopian tube.Antiviral protective immunity induced by major histocompatibility complex class I molecule-restricted viral T-lymphocyte epitopes inserted in various positions in immunologically self and nonself proteins.Mutated mitogen-activated protein kinase: a tumor rejection antigen of mouse sarcomaTherapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccinesCytotoxic T lymphocytes to an unmutated tumor rejection antigen P1A: normal development but restrained effector function in vivo.Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes.Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes.Design and development of synthetic peptide vaccines: past, present and future.Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide.Multiple roles for CD4+ T cells in anti-tumor immune responses.p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge.Harnessing the antigenic fingerprint of each individual cancer for immunotherapy of human cancer: genomics shows a new way and its challenges.T cell immunotherapy for melanoma from bedside to bench to barn and back: how conceptual advances in experimental mouse models can be translated into clinical benefit for patients.Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice.Spontaneous rejection of intradermally transplanted non-engineered tumor cells by neutrophils and macrophages from syngeneic strains of mice.Combination of p53-DC vaccine and rAd-p53 gene therapy induced CTLs cytotoxic against p53-deleted human prostate cancer cells in vitro.Differential susceptibility of cells expressing allogeneic MHC or viral antigen to killing by antigen-specific CTL.Immunobiology of gliomas: new perspectives for therapy.Enhancement of natural killer cytotoxicity delayed murine carcinogenesis by a probiotic microorganism.Amino acid modifications in the wild type sequence p53 232-240 overcome the poor immunogenicity of this self tumour epitope.Cytokine gene therapy of mesothelioma. Immune and antitumor effects of transfected interleukin-12.Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: studies with the model tumor antigen beta-galactosidase and the BALB/c Meth A p53 tumor-specific antigen.Effect of oral administration of Butyrivibrio fibrisolvens MDT-1, a gastrointestinal bacterium, on 3-methylcholanthrene-induced tumor in mice.
P2860
Q24678508-EEA1D27C-140C-4E64-B8CE-BAA9CC47B5D9Q24814703-72207EAD-8758-4763-A877-E91789540CF9Q29620594-56781CE5-478F-45FA-BE04-7EBE881E05BBQ30436422-0842B69F-B0E7-441C-A222-B1C0E9C167B3Q30442838-305B7F74-59E4-4BA0-A670-AB5FF15594C3Q30493889-46EE3A9A-3D92-47D4-A6A9-038C0198E9E4Q30863574-E1652583-FA8C-4768-9214-7B430ECD0D56Q33234400-2ED64F07-97C3-428C-AA81-68E5E961203FQ33582372-5498B49A-1802-48F5-8866-13422B3DCB20Q33638172-C40C219E-B551-4125-8C45-1BD561B9FC85Q33836352-D6C16C98-3BE7-4744-A1D5-1889E03198DCQ33939602-482CFF49-3A27-4137-8AE5-E0679A77A740Q33999909-AFBC31B0-77A7-4EAD-8352-3097E8E4A2C8Q34577679-3D4EA295-E7E6-4D52-8BF3-53E9B1138A4AQ34669820-3DEF20C8-4370-49CD-BC97-5CA533A42C69Q35049933-C28BD990-F0C4-4FBC-A5D3-B57581745700Q35071688-8AE80A7F-424A-407A-B4C1-63F208DEB5BEQ35773825-025899AC-8785-4E6E-BD0E-A63647E1F87BQ35838303-7661FBA1-A073-4312-BCBD-BCA71B8FDF4EQ36184608-B168CB82-5716-493A-BE75-E2733C7EEE69Q36366405-169A28A9-F0F7-46EA-9817-9F85911F56D5Q36367821-A771741E-D91A-4093-82D2-3E97A495F84EQ36376876-13C9CB1F-E4C1-4AB2-9D6C-83CC06AD4004Q36380515-3047D852-7CD4-4691-869A-E658A98A03A2Q36899093-180FFA5A-89D5-4445-A1B8-24A289B47FBFQ37049451-C34669E7-5B65-4B03-A293-352FDE4B7159Q37118150-353A6D67-4D8E-404F-9D53-8CB1DCF813E7Q37604767-B1E8850E-398A-4D44-B106-5333311A30F7Q38100592-8EB72C31-A551-4F10-978C-780BF4EA7A6AQ38101679-B9A02777-54A8-4C8C-9756-B171C16A25CAQ38259896-BB3FEA1D-CF4A-4DB7-945A-1086F7D5975CQ39497120-E2DA1C6C-30F3-4664-8E07-B09A1F1F06A8Q40169855-CA7C23CF-512F-426D-AFC5-C14A5CC18B76Q40597206-5109BBAB-362E-4FDA-B04B-BEA1E04D61AEQ41650683-356932F3-0E94-49AE-A129-32BB5F1F1E5CQ43564045-2A2D7639-8250-4680-A2C7-E66051E9CEE4Q44083202-4650D87B-F964-46E3-B4E6-8E4B4F39DAC5Q45861749-D9980DB1-DFEF-43C2-8210-4344C24AB2EDQ45862136-1908A266-74EB-4185-B82B-25783B3AC81FQ46957665-278E4CE8-EC9F-4D55-AB5F-F90585106D89
P2860
A mouse mutant p53 product recognized by CD4+ and CD8+ T cells.
description
1994 nî lūn-bûn
@nan
1994 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
A mouse mutant p53 product recognized by CD4+ and CD8+ T cells.
@ast
A mouse mutant p53 product recognized by CD4+ and CD8+ T cells.
@en
type
label
A mouse mutant p53 product recognized by CD4+ and CD8+ T cells.
@ast
A mouse mutant p53 product recognized by CD4+ and CD8+ T cells.
@en
prefLabel
A mouse mutant p53 product recognized by CD4+ and CD8+ T cells.
@ast
A mouse mutant p53 product recognized by CD4+ and CD8+ T cells.
@en
P2093
P2860
P356
P1476
A mouse mutant p53 product recognized by CD4+ and CD8+ T cells.
@en
P2093
P2860
P304
P356
10.1073/PNAS.91.8.3171
P407
P577
1994-04-01T00:00:00Z